Rucaparib has an absolute oral bioavailability of 36%. Steady state is reached following a 1-week treatment. Rucaparib can be dosed with or without food.

Rucaparib is eliminated through both metabolism and excretion.

Body weight, body mass index, age, race, sex, cytochrome P450 phenotypes, mild-to-moderate renal or hepatic impairment, and concomitant proton pump inhibitors have no clinically significant effects on the pharmacokinetics of rucaparib.

Rucaparib has a manageable clinical drug–drug interaction profile as a perpetrator of cytochrome P450 enzymes and transporters.

An exposure–response analysis suggests dose-dependent efficacy and safety and supports the rucaparib starting dose of 600 mg twice daily.